期刊
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
卷 67, 期 -, 页码 196-207出版社
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2013.06.041
关键词
N-Aryl-6-methoxy-1,2,3,4-tetrahydroquinolines; Cytotoxicity; Tubulin polymerization inhibitors; Colchicine binding site
资金
- Natural Science Foundation of China (NSFC) [81120108022, 30930106]
- NIH from the National Cancer Institute [CA17625-32]
- Taiwan Department of Health, China Medical University Hospital Cancer Research Center of Excellence [DOH100-TD-C-111-005]
Structural optimizations of the prior lead 1a led to the discovery of a series of N-aryl-6-methoxy-1,2,3,4-tetrahydroquinoline derivatives as a novel class of tubulin polymerization inhibitors targeted at the colchicine binding site. The most active compound 6d showed extremely high cytotoxicity against a human tumor cell line panel (A549, KB, KBvin, and DU145) with GI(50) values ranging from 1.5 to 1.7 nM, significantly more potent than paclitaxel, especially against the drug-resistant KBvin cell line, in the same assays. Analogs 5f, 6b, 6c, and 6e were also quite potent, with a GI(50) range of 0.011-0.19 mu M. In further studies, active compounds 6b e and 5f significantly inhibited tubulin assembly, with IC50 values of 0.92 -1.0 mu M and strongly inhibited colchicine binding to tubulin, with inhibition rates of 75-99% (at 5 mu M), comparable with or more potent than combretastatin A-4 (IC50 0.96 mu M). Current studies included design, synthesis, and biological evaluations of 24 new compounds (series 3-6). Related SAR analysis, molecular modeling, and evaluation of essential drug-like properties, i.e. water solubility, log P, and in vitro metabolic stability, were also performed. (C) 2013 Elsevier Masson SAS. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据